Watch for completion of the BLA submission in Q4 2026 and FDA acceptance for priority review. Approval would transform PTC's rare disease franchise with a one-time gene therapy addressing a chronic ERT market.
Price Chart
Executive Summary
PTC Therapeutics completed its acquisition of ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics. A rolling BLA submission to the FDA for accelerated approval is expected in Q4 2026. This adds a late-stage pipeline asset with regulatory designations (Orphan Drug, Fast Track, RMAT) to PTC's rare disease portfolio.
Key Facts
- Acquisition of ST-920 (isaralgagene civaparvovec) from Sangamo Therapeutics completed
- ST-920 is a one-time AAV gene therapy for Fabry disease, currently in BLA stage
- Rolling BLA submission to FDA for accelerated approval expected to be completed in Q4 2026
- ST-920 has FDA Orphan Drug, Fast Track, and RMAT designations; EMA Orphan Medicinal Product and PRIME eligibility; UK MHRA Innovative Licensing and Access Pathway
- Clinical data showed long-term α-Gal A enzyme production, reduced Gb3 levels, and durable clinical benefit
Financial Impact
Deal value not disclosed; potential regulatory milestone payments may be owed to Sangamo
Risk Factors
- Regulatory risk: FDA may not accept the BLA or grant accelerated approval
- Commercial risk: Reimbursement and adoption vs. established ERT therapies
- Manufacturing risk: Scaling AAV gene therapy production
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302885167 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Institutional Cluster | $61.07 | awaiting T+1 | — | $62.09 (+1.67%) |
Oct 16, 2026 11d ago | Insider Cluster | $61.53 $62.92 | ▲ +2.26% | ▲ +1.92% | $62.09 (+0.91%) |
Oct 9, 2026 18d ago | 144 | $62.92 $59.92 | ▼ −4.77% | ▼ −4.76% | $62.09 (−1.32%) |
Oct 7, 2026 20d ago | 144 | $62.56 $64.70 | ▲ +3.42% | ▲ +2.82% | $62.09 (−0.75%) |
Oct 6, 2026 21d ago | 144 | $63.23 $62.56 | ▼ −1.06% | ▼ −0.64% | $62.09 (−1.80%) |
Sep 21, 2026 5w ago | Press Release | $65.96 $62.34 | ▼ −5.49% | ▼ −4.77% | $62.09 (−5.87%) |
Aug 21, 2026 9w ago | Insider Cluster | $71.06 $73.47 | ▲ +3.39% | ▲ +3.07% | $62.09 (−12.62%) |
Jul 16, 2026 14w ago | Insider Cluster | $78.59 $78.01 | ▼ −0.74% | ▼ −0.58% | $62.09 (−21.00%) |
Jul 16, 2026 14w ago | Press Release | $78.52 | awaiting T+1 | — | $62.09 (−20.92%) |
Jul 13, 2026 15w ago | Insider Cluster | $78.06 $78.84 | ▲ +1.00% | ▲ +0.60% | $62.09 (−20.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers